Just weeks into its life as a publicly traded company, Solid Biosciences Inc (NASDAQ: SLDB) caught the eyes of four analysts who assumed coverage Tuesday with a mix of Holds and Buys.
Here is what one of the more bearish critics had to say. The Rating
Goldman Sachs analyst Salveen Richter. Read More.
BTIG initiated coverage on United Therapeutics Corporation (NASDAQ: UTHR) Monday with a Neutral rating. Analyst Hartaj Singh believed a “late-2017 patent cliff for 3 out of 4 of its top products that could reduce 2018 adjusted EPS to 2013 levels (~$6-7/share) is offset by the blue sky. Read More.